Internal Medicine, Hematology & Oncology · Marmora, NJ
NPI
1891782371
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
210 S Shore Rd, Suite 106
Marmora, NJ, 08223
Phone (609) 390-7888
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.9M
134,339 services
Medicare patients, 2024
687
Average age 76
Drug cost, 2024
$3.1M
835 prescriptions
Company payments, 2025
$2,484
From 40 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Hemang U Dave was code J0881 (injection, darbepoetin alfa, 1 microgram (non-esrd use)), 21,700 times for 34 patients. In total Hemang U Dave billed 134,339 services in 126 codes, and Medicare paid $1.9M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-03-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 21,700 | 34 | $2.37 | $51K |
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 15,660 | 15 | $0.22 | $3,377 |
| J0897 Injection, denosumab, 1 mg | Office | 5,400 | 48 | $20.59 | $111K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 5,240 | 24 | $6.50 | $34K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 3,800 | 30 | $15.84 | $60K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,896 | 47 | $0.09 | $170 |
| 85025 Blood Count | Office | 1,272 | 492 | $7.60 | $9,664 |
| 36415 Venipuncture Blood Collection | Office | 1,178 | 460 | $8.64 | $10K |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 790 | 21 | $0.26 | $202 |
| 99214 Office E&M - Established | Office | 541 | 337 | $100.80 | $55K |
| 96367 Intravenous Infusion, Hydration | Office | 416 | 88 | $24.02 | $9,992 |
| 96372 Injection Administration | Office | 412 | 116 | $11.93 | $4,916 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 284 | 176 | $12.98 | $3,686 |
| J3490 Unclassified drugs | Office | 258 | 82 | $0.32 | $83.48 |
| 96413 Chemotherapy Administration | Office | 217 | 54 | $110.54 | $24K |
By year: 2022 $2.3M for 158,932 services; 2023 $1.5M for 112,336 services; 2024 $1.9M for 134,339 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,272 | 492 | $7.60 | $9,664 |
| 36415 Venipuncture Blood Collection | 1,178 | 460 | $8.64 | $10K |
| 85610 Clinical Chemistry | 94 | 25 | $4.20 | $395 |
Medicare prescription drug claims, 2024
In 2024, the drug Hemang U Dave prescribed most often to Medicare patients was Eliquis (Apixaban), with 77 prescriptions and refills. In total Hemang U Dave wrote 835 Medicare prescriptions that cost $3.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 77 | 184 | 23 | $101K |
| Warfarin Sodium Generic | 77 | 209 | 19 | $1,336 |
| Tamoxifen Citrate Generic | 50 | 150 | 16 | $1,089 |
| Imbruvica Ibrutinib | 50 | 50 | Under 11 | $622K |
| Letrozole Generic | 45 | 131 | 13 | $910 |
| Revlimid Lenalidomide | 34 | 34 | Under 11 | $678K |
| Raloxifene Hcl Generic | 29 | 87 | Under 11 | $1,886 |
| Xarelto Rivaroxaban | 29 | 63 | Under 11 | $34K |
| Exemestane Generic | 27 | 61 | Under 11 | $1,725 |
| Gabapentin Generic | 26 | 46 | Under 11 | $316 |
| Prednisone Generic | 25 | 49 | Under 11 | $201 |
| Hydroxyurea Generic | 25 | 64 | Under 11 | $1,256 |
| Ondansetron Odt Ondansetron | 21 | 21 | 15 | $241 |
| Valacyclovir Valacyclovir Hcl | 20 | 56 | Under 11 | $893 |
| Imatinib Mesylate Generic | 20 | 20 | Under 11 | $1,136 |
Brand drugs: - claims; generic drugs: 538 claims; opioid claims: 11.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Hemang U Dave $2,484 ($2,484 in general payments such as food, travel and fees) from 40 companies. The largest payer was Janssen Biotech, Inc. with $203.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 6 | $203 |
| Novartis Pharmaceuticals Corporation NVS | 8 | $172 |
| Sobi, Inc SOBI.ST | 5 | $169 |
| AstraZeneca Pharmaceuticals LP AZN | 8 | $144 |
| Daiichi Sankyo Inc. 4568.T | 3 | $137 |
| Pfizer Inc. PFE | 9 | $137 |
| Merck Sharp & Dohme LLC MRK | 7 | $135 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 5 | $95.14 |
| Celgene Corporation BMY | 5 | $82.91 |
| Tempus AI, Inc TEM | 3 | $73.88 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.